MOR News and Press, MorphoSys AG From 06/04/21

Presentation will be available on demand as part of the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting BOSTON, MA and WILMINGTON, DE / ACCESSWIRE / June 4, 2021 / MorphoSys US Inc., a fully owned subsidiary of MorphoSys AG (FSE:MOR) (NASDAQ:MOR), and Incyte (NASDAQ:I...

Shares of MorphoSys (NASDAQ: MOR) sank 11.5% this week as of the market close on Thursday. The decline stemmed from the German drugmaker's announcement on Wednesday that it plans to acquire Constellation Pharmaceuticals (NASDAQ: CNST) for $1.7 billion. MorphoSys also said th...

The stock of Constellation Pharmaceuticals (NASDAQ: CNST) was absolutely crushing it this week, up 70.6% as of the market close on Thursday. The catalyst behind this impressive performance was the announcement on Wednesday that German drugmaker MorphoSys (NASDAQ: MOR) plans ...

Constellation Pharmaceuticals ([[CNST]] +67.2%) has risen more than two-thirds in value after agreeing to be acquired by German biotech MorphoSys AG (MOR) in a deal valued at $1.7B.The offer price of $34.00 per share in cash for Constellation’s common stock indicates a premium of ...

Shares of Constellation Pharmaceuticals (NASDAQ: CNST) had skyrocketed 66.7% as of 12:01 p.m. EDT on Wednesday. The huge gain came after MorphoSys (NASDAQ: MOR) announced that it will acquire Constellation for $1.7 billion. MorphoSys was attracted to Constellation for it...

iRhythm Technologies (IRTC) -15% as CEO departs; Company reaffirms guidanceOrbital Energy Group (OEG) -13%.Protalix BioTherapeutics (PLX) -10% Protalix Biotherapeutics and Chiesi Global Rare Diseases provide update regarding clinical development of PRX-102 for treatment of fabr...

MUNICH, GERMANY and CAMBRIDGE, MA / ACCESSWIRE / June 2, 2021 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR) ("MorphoSys"), announces today that it has entered into a definitive agreement with Constellation Pharmaceuticals, Inc. (NASDAQ: CNST) ("Constellation") whereby MorphoSys will acquire Constell...

Royalty Pharma to provide tailored funding solution to enable MorphoSys’ acquisition of Constellation Pharmaceuticals Investment is anchored by royalties on Janssen’s Tremfya Partnership also includes royalties on four development-stage therapies, Developme...

Accelerates Growth Strategy by Adding Two Mid- to Late-Stage Product Candidates: Pelabresib (CPI-0610) and CPI-0209 Bolsters Position in Hematology-Oncology and Expands into Solid Tumors Best-in-Class Combined Discovery and Development Capabilities Accelerates Ability ...

ASCO is a very important cancer clinical research meeting. We identified 70 smid-cap cancer companies presenting updated clinical data at ASCO21. 13 companies' value increased by over 10% with ASCO21 info release thus far. PDSB is an early ASCO21 mover, with its HPV vaccine ca...